



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: +044-25267517/25270992, FAX: 91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com
CIN: L24294TN1995PLC030698

Ref: BPL/803/ 13-14

13.02.2014

Listing Department
The Bombay Stock Exchange Limited
P J Towers
Dalal Street
Mumbai - 400 001
SCRIP CODE: 532989

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai - 400051
SCRIP SYMBOL: BAFNAPHARM

ISIN: INE 878101014

Dear Sir

Sub: Outcome of the Board meeting held on 13.02.2014 - Reg.

We wish to inform you that, among the others following is the outcome of the meeting of the Board of Directors of the company held on Thursday the 13th day of February, 2014:

- Approved the unaudited quarterly results for the quarter ending 31st December, 2013

Also find enclosed the Limited Review Report for the quarter ended 31st December, 2013 as per Clause 41 of the Listing Agreement.

These are for your kind information & records and treat this as compliance with Listing Agreement.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For BAFNA PHARMACEUTICALS LIMITED


Bafna Mahaveer Chand
Managing Director

Encl: As above.

BAFNA PHARMACEUTICALS LIMITED

Regd office: 299, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter and Nine Months Ended 31 st December 2013

Part I						
(Rs. In lakhs)						
Particulars	STANDALONE					
	3 months ended (31-12-2013)	Preceding 3 months ended (30-09-2013)	Corresponding 3 months ended (31-12-2012) in the previous Year	Year to date for the current period ended	Year to date for the previous year ended	Previous Year ended
	Unaudited	Unaudited	Unaudited	(31-12-2013) Unaudited	(31-12-2012) Unaudited	(31-03-2013) Audited
1. Income form Operations						
(a) Net Sales/Income from Operations (net of excise duty)	4,671.58	4,699.27	2,778.54	13,824.63	11,647.44	16,713.59
(b) Other Operating Income	-	-	-	-	385.39	-
Total income from operations (net)	4,671.58	4,699.27	2,778.54	13,824.63	12,032.83	16,713.59
2. Expenditure						
a. Cost of materials consumed	1,632.87	2,773.16	1,125.25	5,408.55	3,245.63	4,269.97
b. Purchase of stock-in-trade	1,233.03	594.75	958.55	4,513.90	5,849.20	8,492.23
c. Changes in inventories of finished goods,WIP and stock-in-trade	319.51	121.20	(515.68)	27.10	(378.11)	(138.18)
d. Employees benefits expense	384.72	377.55	348.01	1,092.37	780.10	1,059.86
e. Depreciation and amortisation expense	127.77	142.65	202.44	449.91	538.88	759.04
f. Other expenditure (Any item exceeding 10% of the total expenses relating to continuing operations)	538.97	171.19	258.43	1,064.87	702.66	932.70
Total Expenses	4,236.87	4,180.49	2,377.00	12,556.69	10,738.35	15,375.42
3. Profit/(Loss) from Operations before Other Income, finance cost and Exceptional Items (1-2)	434.71	518.78	401.54	1,267.94	1,294.47	1,338.17
4. Other Income	20.93	(42.57)	51.72	103.23	143.42	303.05
5. Profit/(Loss) from ordinary activities before finance cost and Exceptional Items (3+/- 4)	455.64	476.21	453.26	1,371.17	1,437.89	1,641.21
6. Finance Costs	282.70	301.26	277.78	866.37	795.99	1,123.27
7. Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5+/- 6)	172.94	174.96	175.48	504.79	641.90	517.94
8. Exceptional items	-	-	-	-	-	-
9. Profit / Loss from Ordinary Activities before tax (7+/- 8)	172.94	174.96	175.48	504.79	641.90	517.94
10. Tax expense	62.80	56.29	34.63	170.59	168.09	130.02
11. Net Profit / Loss from Ordinary Activities after tax (9 +/- 10)	110.14	118.67	140.85	334.20	453.81	387.92
12. Extraordinary item (net of tax expense Rs. _____ lacs)	-	-	-	-	-	-
13. Net Profit/ Loss for the period (11 +/- 12)	110.14	118.67	140.85	334.20	453.81	387.92
14. Share of profit/ (loss) of associates*	-	-	-	-	-	-
15. Minority Interest*	-	-	-	-	-	-
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 +/- 14 +/- 15)*	110.14	118.67	140.85	334.20	453.81	387.92
17. Paid up equity share capital (Face value of Rs.10/- each)	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19 (i). Earnings Per Share (EPS) (before extraordinary items) (not annualised)	-	-	-	-	-	-
a) Basic	1.79	1.20	0.75	1.79	2.43	2.08
b) Diluted	1.79	1.20	0.75	1.79	2.43	2.08
19 (ii). Earning per share (after extraordinary items) (not annualised)	-	-	-	-	-	-
a) Basic	1.79	1.20	0.75	1.79	2.43	2.08
b) Diluted	1.79	1.20	0.75	1.79	2.43	2.08

Part II Particulars	STANDALONE					
	3 months ended (31.12.2013)	Preceding 3 months ended (30.09.2013)	Corresponding 3 months ended (31.12.2012) in the previous Year	Year to date for the current period ended 31.12.2013	Year to date for the previous year ended (31.12.2012)	Previous year ended 31.03.2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars of Shareholding						
1. Public Shareholding						
- No. of shares	11,847,257	12,896,196	11,559,886	11,847,257	11,559,886	11,684,158
- Percentage of shareholding	63.50	69.13	61.96	63.50	61.96	62.63
2. Promoters and promoter group shareholding**						
a) Pledged/Encumbered						
- Number of shares	1,530,000	1,530,000	1,283,000	1,530,000	1,283,000	1,613,000
- Percentage of shares (as a% of the total shareholding of promoter and promoter)	22.47	26.56	18.08	22.47	18.08	23.13
- Percentage of shares (as a% of the total share capital of the Company)	8.20	8.20	6.88	8.20	6.88	8.65
b) Non-encumbered						
- Number of Shares	5,279,078	4,230,139	5,813,449	5,279,078	5,813,449	5,359,177
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	77.53	73.44	81.92	77.53	81.92	76.87
- Percentage of shares (as a % of the total share capital of the company)	28.30	22.67	31.16	28.30	31.16	28.73

NOTES

- 1 The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 13.02.2014
- 2 Status of Investor Complaints:-
 Opening balance Nil
 Pending at the beginning of the quarter Nil
 No. of complaints received and disposed off during the quarter Nil
 Complaints pending at the end of the quarter Nil
- 3 The Company operates only in one segment, i.e. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- 4 The Limited Review as required under Clause 41 of the Listing Agreement has been completed by the statutory Auditors for the Quarter ended 31.12.2013
- 5 The Revised Schedule VI has become applicable to the Company for the presentation of Financial statement, accordingly the previous year/ period figures have been regrouped / reclassified wherever necessary
- 6 The MD, CEO and Manager-Accounts & Finance certificate in respect of the above results in terms of the requirement of Clause 41 of the Listing Agreement has been placed before the Board of Directors.
- 7 The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Third quarter of the Financial year.

For BAFNA PHARMACEUTICALS LIMITED

BAFNA MAHAVEER DHAND
MANAGING DIRECTOR

Place : Chennai
Date : 13.02.2014

